Bionomics (BNOX) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChart

BNOX Stock Forecast


Bionomics stock forecast is as follows: an average price target of $6.00 (represents a 3038.08% upside from BNOX’s last price of $0.19) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

BNOX Price Target


The average price target for Bionomics (BNOX) is $6.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 3038.08% upside from BNOX's last price of $0.19.

BNOX Analyst Ratings


Buy

According to 3 Wall Street analysts, Bionomics's rating consensus is 'Buy'. The analyst rating breakdown for BNOX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Bionomics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 19, 2022Joshua SchimmerEvercore ISI$6.00$5.891.87%3038.08%
Row per page
Go to

The latest Bionomics stock forecast, released on Dec 19, 2022 by Joshua Schimmer from Evercore ISI, set a price target of $6.00, which represents a 1.87% increase from the stock price at the time of the forecast ($5.89), and a 3038.08% increase from BNOX last price ($0.19).

Bionomics Price Target by Period


1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.19$0.19$0.19
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of Bionomics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Bionomics's last price of $0.19. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Jun 13, 2024H.C. WainwrightBuyBuyHold
Mar 10, 2023Evercore ISI-OutperformUpgrade
Dec 19, 2022William BlairOutperformOutperformHold
Row per page
Go to

Bionomics's last stock rating was published by H.C. Wainwright on Jun 13, 2024. The company gave BNOX a "Buy" rating, the same as its previous rate.

Bionomics Financial Forecast


Bionomics Revenue Forecast

Sep 24Jun 24
Revenue--
Avg Forecast-$2.64M
High Forecast-$2.64M
Low Forecast-$2.64M
# Analysts-1
Surprise %--

Bionomics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. BNOX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Bionomics EBITDA Forecast

Sep 24Jun 24
# Analysts-1
EBITDA--
Avg Forecast-$-528.77K
High Forecast-$-528.77K
Low Forecast-$-528.77K
Surprise %--

undefined analysts predict BNOX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Bionomics's previous annual EBITDA (undefined) of $NaN.

Bionomics Net Income Forecast

Sep 24Jun 24
# Analysts-1
Net Income--
Avg Forecast$4.23B$-2.64B
High Forecast$4.23B$-2.64B
Low Forecast$4.23B$-2.64B
Surprise %--

Bionomics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BNOX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Bionomics SG&A Forecast

Sep 24Jun 24
# Analysts-1
SG&A--
Avg Forecast-$302.17M
High Forecast-$302.17M
Low Forecast-$302.17M
Surprise %--

Bionomics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to BNOX last annual SG&A of $NaN (undefined).

Bionomics EPS Forecast

Sep 24Jun 24
# Analysts-1
EPS--
Avg Forecast$2.27$-1.42
High Forecast$2.27$-1.42
Low Forecast$2.27$-1.42
Surprise %--

According to undefined Wall Street analysts, Bionomics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BNOX previous annual EPS of $NaN (undefined).

Bionomics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
BNOXBionomics$0.19$6.003057.89%Buy
PMVPPMV Pharmaceuticals$1.64$24.751409.15%Buy
ANTXAN2 Therapeutics$1.08$8.75710.19%Buy
AVTEAerovate Therapeutics$2.72$13.00377.94%Hold
ANEBAnebulo Pharmaceuticals$1.89$6.00217.46%Buy
ACRVAcrivon Therapeutics$7.85$22.00180.25%Buy
RZLTRezolute$5.44$13.50148.16%Buy
ADAGAdagene$3.05$5.0063.93%Buy

BNOX Forecast FAQ


Yes, according to 3 Wall Street analysts, Bionomics (BNOX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of BNOX's total ratings.

Bionomics (BNOX) average price target is $6 with a range of $6 to $6, implying a 3038.08% from its last price of $0.191. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for BNOX stock, the company can go up by 3038.08% (from the last price of $0.191 to the average price target of $6), up by 3038.08% based on the highest stock price target, and up by 3038.08% based on the lowest stock price target.

BNOX's average twelve months analyst stock price target of $6 supports the claim that Bionomics can reach $0 in the near future.

BNOX's analysts financial forecasts for the fiscal year (Jun 2024) are as follows: average revenue is $2.64M (high $2.64M, low $2.64M), average EBITDA is $-529K (high $-529K, low $-529K), average net income is $-2.641B (high $-2.641B, low $-2.641B), average SG&A $302.17M (high $302.17M, low $302.17M), and average EPS is $-1.419 (high $-1.419, low $-1.419).